Evidence map›Paper›PMID 40903341›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Stress-induced nuclear GAPDH: Scientific update and clinical application.

Parimala Vedula, Koko Ishizuka, Arisa Hayashida, Kota Sueo, Akira Sawa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Protein oxidation in crowded environments.The Biochemical journal · 2026
    Review
  3. Article
  4. Gasotransmitter signaling in the brain: New frontiers for therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Parimala VedulaDepartments of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Departments of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Koko IshizukaDepartments of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Arisa HayashidaDepartments of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kota SueoDepartments of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Akira SawaDepartments of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Departments of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Departments of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Departments of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Departments of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address: asawa1@jhmi.edu.

Funding

Project 3P50MH136297 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Elie Laurent Younes · 2024 to 2026
$12.8M
NIMH NIH HHS P50 MH136297
6 · The paper itself

Abstract

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is known as a moonlighting protein beyond its original glycolytic function. Stress-induced nuclear translocation of GAPDH has been reproducibly reported, which results in variety types of cellular responses, including cell death and dysfunction. Blocking this stress-induced cascade has been regarded as a target of drug discovery and development for human disease conditions, particularly for neurological and psychiatric diseases. There are promising small compounds that can block this cascade in cell and animal models. Nevertheless, the clinical trials for Parkinson's disease and amyotrophic lateral sclerosis with one of these compounds Omigapil were unsuccessful. Including these failure cases, this review article discussed the scientific frontline of GAPDH, particularly stress-induced nuclear GAPDH, and its potential for clinical applications.

Indexed as

Cell NucleusGlyceraldehyde-3-Phosphate DehydrogenasesStress, PhysiologicalAnimalsHumansGlyceraldehyde-3-Phosphate DehydrogenasesCellular homeostasisGlyceraldehyde 3-phosphate dehydrogenase (GAPDH)Moonlighting proteinNucleusPosttranslational modificationS-nitrosylationStress responseTherapeutics

Identifiers

PMID40903341
PMCPMC12664512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.